riboflavin
AssetAlso called INS NO. 101, NCI-0033298, NSC-33298, E-b2
Precursor of flavin cofactors FMN and FAD required for cellular oxidation-reduction reactions.
- Stage
- Approved
- Modality
- Supplement
- Target
- Not known
- 2
- Indications
- 36
- Trials
- 2
- Developers
Indications
3No named disease
Approved, open.fda.gov, Jan 1, 1993
Keratoconus
Phase 3, Terminated, NCT01972854, clinicaltrials.gov, Oct 17, 2026
Gut microbiota
Phase 2, Completed, NCT02929459, clinicaltrials.gov, Oct 17, 2026
In the full profile
- Owner and partners2
- Trials36
- Evidence for its targets1
- Competitors2
- Aging relevance1
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.